Ancilia Biosciences is thrilled to announce the successful completion of a $3 million funding round aimed at accelerating the development of its groundbreaking CRISPR-based bacterial therapies. Founded with the mission to harness the natural power of gene editing, Ancilia is at the forefront of biotechnological advancement, creating innovative solutions that address a variety of health and environmental challenges. This latest infusion of capital will allow the company to expand its research capabilities, streamline its product development pipeline, and enhance its collaborative efforts with academic and industrial partners. With this funding, Ancilia aims to further explore the vast potential applications of CRISPR technology, including targeted microbial treatments for gut health, antibiotic resistance, and sustainable agriculture practices. By tapping into the intricacies of bacterial genetics, Ancilia is committed to improving human and ecological well-being through novel therapeutic interventions. Our visionary team is dedicated to pushing the boundaries of what is possible in biotechnology, and this financial backing is a testament to their hard work and innovation. As we embark on this exciting journey, we look forward to sharing our progress and demonstrating the disruptive impact of our products in the healthcare and environmental sectors. Thank you to our investors for believing in Ancilia's mission; together, we are poised to revolutionize the future of bacterial therapies and reshape the landscape of health and sustainability.
Revolutionizing Bacterial Therapies: Ancilia Biosciences Secures $3M in Pre-Seed Round
Recently funded · $3.0M Pre-seedBiotechnology
Get the full Ancilia Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Pre-seed rounds
Companies that recently closed a Pre-seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Dognosis India | Pre-seed | $1.5M | today |
| 2 | Dognosis India | Pre-seed | $1.5M | today |
